ALTHE Theraclion SA

0.6296USD0.5740 EUR · EPA-2.71%Mkt Cap: 46.45M USDP/E: —

Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive …

Key Statistics

Company
Market Cap46.45M USD
Enterprise Value—
Revenue (TTM)526.46K USD
Gross Profit-3.13M USD
Net Income (TTM)-6.24M USD
Revenue/Share0.01 USD
Last Price0.6296 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees40
CountryFR
SectorHealthcare
IndustryMedical Devices
ISINFR0010120402
Valuation
P/E (Trailing)—
P/E (Forward)-5.81
PEG—
EV/EBITDA—
EV/Revenue—
P/S88.23
P/B-13.35
EPS (TTM)-0.10 USD
EPS (Forward)-0.11 USD
52W Range
0.440933% of range1.020
52W High1.020 USD
52W Low0.4409 USD
Profitability
Gross Margin-240.81%
Oper. Margin-1831.88%
EBITDA Margin0.00%
Profit Margin-479.76%
ROE219.81%
ROA-38.21%
ROIC—
ROCE-59.68%
Growth
Revenue Growth-20.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.85M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Net Debt/FCF—
Balance Sheet
Debt/Equity-1.91
Current Ratio—
Quick Ratio—
Book Value/Sh-0.05 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)2.228 USD
Upside (mean)+254.0%
Target Range2.228 USD – 2.228 USD
# Analysts1
Ownership
Shares Out.73.78M
Float32.35M
Insiders67.76%
Institutions0.00%
Technical
SMA 500.7172 (-12.2%)
SMA 2000.6716 (-6.3%)
Beta0.42
S&P 52W Chg12.00%
Avg Vol (30d)117.58K
Avg Vol (10d)254.32K
Technical Indicators
RSI (14)39.3
MACD-0.0165
MACD Signal-0.0056
MACD Hist.-0.0109
BB Upper0.8232 USD
BB Middle0.7127 USD
BB Lower0.6022 USD
BB Width31.01%
ATR (14)0.0535 USD
Vol Ratio (20d)0.07x

About Theraclion (EPA: ALTHE)

›

Theraclion (EPA: ALTHE) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 40 employees.

The shares were at 0.5740 EUR on 19 November 2026, down 11.1% over 52 weeks. Its 52-week range is 0.4020 EUR to 0.9300 EUR: the price is 38.3% below the high and 42.8% above the low.

Its market capitalisation is 42.35M EUR.

Theraclion reports return on equity of 219.8% and revenue down 20.9% year over year.

Its Piotroski F-score is 4 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 2.032 EUR is 254.0% above the current price.